Loading...

Purified anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_Purified_041106
C57BL/6 mouse splenocytes were stained with purified CD8 (clone 53-6.7) (filled histogram) or rat IgG2a, κ isotype control (open histogram), followed by anti-rat IgG FITC.
  • 53-6dot7_Purified_041106
    C57BL/6 mouse splenocytes were stained with purified CD8 (clone 53-6.7) (filled histogram) or rat IgG2a, κ isotype control (open histogram), followed by anti-rat IgG FITC.
  • 53-6dot7_Purified_IHC_011917
    C57BL/6 frozen mouse spleen section was fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS for 30 minutes at room temperature. Then the section was stained with 10 µg/mL of purified anti-mouse CD8a (clone 53-6.7), 10 µg/mL of Alexa Fluor® 647 anti-CD20 (green) overnight at 4°C, followed by 2.5 µg/mL of Alexa Fluor® 594 anti-rat IgG2a (clone MRG2a-83) (red) for two hours at room temperature. The image was captured by 10X objective.
  • 53-6dot7_Purified_IHC_102418
    Fresh, frozen mouse spleen was stained with purified CD8a clone 53-6.7 conjugated and detected with a Cy3 CODEX™ oligonucleotide duplex (red). Samples were counterstained with B220 FITC (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Compare all formats
Cat # Size Price Save
100701 50 µg ¥6,410
100702 500 µg ¥23,540
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/mL
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF®, IHC-F - Verified
IP - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µL volume. For immunohistochemistry on frozen tissue sections, the suggested use of this reagent is 5.0 - 10 µg per mL. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed
  2. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  3. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  4. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
  5. Tersteegen A, et al. 2021. Infect Immun. 89:. PubMed
  6. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  7. Yu H, et al. 2020. Front Immunol. 11:1773. PubMed
  8. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  9. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  10. Campisi L, et al. 2022. Nature. 606:945. PubMed
  11. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  12. Gerace D, et al. 2023. Cell Rep Med. 4:100879. PubMed
  13. Jeon EY, et al. 2023. Bioeng Transl Med. 8:e10362. PubMed
  14. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  15. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  16. Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed
  17. Kang YA, et al. 2023. J Exp Med. 220:. PubMed
  18. Xu J, et al. 2023. Discov Oncol. 14:68. PubMed
  19. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  20. Murata A, et al. 2020. Front Immunol. 11:775. PubMed
  21. Wang C, et al. 2020. Oncoimmunology. 9:1809947. PubMed
  22. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  23. Kao C, et al. 2005. Int Immunol. 1.824305556. PubMed
  24. Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed
  25. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
  26. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  27. Asthagiri Arunkumar G, et al. 2019. Vaccine. 37:5567. PubMed
  28. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  29. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  30. Rubio‐Patiño C et al. 2018. Cell metabolism. 27(4):828-842 . PubMed
  31. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  32. Goel S, et al. 2017. Nature. 548:471. PubMed
  33. Bradford BM, et al. 2018. Parasite Immunol. 40:e12566. PubMed
  34. Field CS, et al. 2018. Oncoimmunology. 7:e1376154. PubMed
  35. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  36. Boldison J, et al. 2020. Cell Mol Immunol. 17:843. PubMed
  37. Prado C, et al. 2021. J Neuroinflammation. 18:292. PubMed
  38. Haque M, et al. 2021. Viruses. 13:. PubMed
  39. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
  40. Tian K, et al. 2021. J Immunol Res. 2021:6297332. PubMed
  41. Nguyen N, et al. 2022. iScience. 25:103679. PubMed
  42. Hirano J, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  43. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  44. Rossi DC, et al. 2021. J Clin Invest. 131:. PubMed
  45. Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed
  46. Gao J, et al. 2017. Oncol Lett. 14:2954. PubMed
  47. Zhou AC, et al. 2017. Front Immunol. 1.136111111. PubMed
  48. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  49. Kaplanov I, et al. 2019. Proc Natl Acad Sci U S A. 116:1361. PubMed
  50. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  51. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  52. Willimsky G, et al. 2021. Elife. 10:. PubMed
  53. Tian D, et al. 2020. FASEB J. 34:3367. PubMed
  54. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  55. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  56. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  57. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  58. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
  59. Hiramatsu-Asano S, et al. 2021. Front Immunol. 11:616141. PubMed
  60. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  61. Bartsch YC, et al. 2018. Front Immunol. 1.196527778. PubMed
  62. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  63. Recino A, et al. 2019. Gene Ther. 26:40. PubMed
  64. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  65. Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed
  66. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
  67. Guo Y, et al. 2008. Blood. 112:480. PubMed
  68. Wang N, et al. 2021. Mol Ther Oncolytics. 20:71. PubMed
  69. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  70. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  71. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  72. Sharma M, et al. 2020. Nat Commun. 11:661. PubMed
  73. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  74. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  75. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  76. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  77. Hiratsuka S, et al. 2018. EMBO Mol Med. 10:e8643. PubMed
  78. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  79. Furukawa K,et al. 2017. PLoS One. 10.1371/journal.pone.0184901. PubMed
  80. Zhao F, et al. 2018. Cancer Immunol Res. 1.263194444. PubMed
  81. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  82. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  83. Sharba S, et al. 2019. Virulence. 10:97. PubMed
  84. Mori H, et al. 2015. Toxicol Pathol. 43: 883-889. PubMed
  85. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  86. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  87. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  88. Liu H, et al. 2020. J Immunol. 205:1207. PubMed
  89. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  90. Hsiao CC, et al. 2021. Cells. 10:. PubMed
  91. Dooley K, et al. 2021. Mol Ther. 29:1729. PubMed
  92. Dai Z, et al. 2021. JCI Insight. 6: . PubMed
  93. Zhong X, et al. 2020. Proc Natl Acad Sci U S A. 8563:117. PubMed
  94. Zareie P, et al. 2017. J Neuroinflammation. 0.630555556. PubMed
  95. Kim SJ, et al. 2017. Nat Immunol. 18:1016. PubMed
  96. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  97. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  98. Sprouse ML, et al. 2018. JCI Insight. 3:e97322. PubMed
  99. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  100. Sheppard S, et al. 2018. Front Immunol. 1.630555556. PubMed
  101. Sharabi A, et al. 2019. JCI Insight. 4:e126294. PubMed
  102. Chihara N, et al. 2018. Nature. 558:454. PubMed
  103. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  104. Majer O, et al. 2019. Nature. 575:366. PubMed
  105. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  106. Jang SC, et al. 2021. Commun Biol. 4:497. PubMed
  107. You X, et al. 2022. Front Genet. 12:790990. PubMed
  108. Gilfillan CB, et al. 2020. Eur J Immunol. 50:505. PubMed
  109. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  110. Zelazowska MA, et al. 2020. Life Sci Alliance. :3. PubMed
  111. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  112. Kenna T, et al. 2008. Blood. 111:2091. PubMed
  113. King IL, et al. 2017. Mucosal Immunol. 10:1160. PubMed
  114. Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed
  115. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  116. Oyarce K, et al. 2018. Front Immunol. 9:112. PubMed
  117. Tan CL, et al. 2018. Immunohorizons. 0.248611111. PubMed
  118. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  119. Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed
  120. Bajic D, et al. 2020. Mol Cancer Ther. 19:2554. PubMed
  121. Ikezoe T, et al. 2021. Biomolecules. 11:. PubMed
  122. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  123. Dionisio-Santos DA, et al. 2021. Front Neurosci. 15:758677. PubMed
  124. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  125. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
  126. Kakaradov B, et al. 2017. Nat Immunol. 18:422. PubMed
  127. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  128. Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed
  129. Meyers JL, et al. 2018. PLoS One. 13:e0207007. PubMed
  130. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  131. Duncan CG, et al. 2018. G3 (Bethesda). 0.892361111. PubMed
  132. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  133. Ko S, et al. 2005. J Immunol. 175:3309. PubMed
  134. Shissler SC, et al. 2020. Sci Rep. 10:8218. PubMed
  135. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  136. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  137. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
  138. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
  139. Amobi-McCloud A, et al. 2021. Front Immunol. 12:678999. PubMed
  140. Zhang Z, et al. 2020. Front Immunol. 1.844444444. PubMed
  141. Brown ZJ, et al. 2018. Cell Death Dis. 0.805555556. PubMed
  142. Stelekati E, et al. 2018. Cell Rep. 2.445833333. PubMed
  143. Cui X, et al. 2017. J Immunol. 199:4066. PubMed
  144. Zhang C, et al. 2018. Cell Res. 28:323. PubMed
  145. Afzali B, et al. 2017. Nat Immunol. 18:813. PubMed
  146. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
  147. Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
  148. Lee B, et al. 2019. Front Immunol. 0.561805556. PubMed
  149. Sami E, et al. 2020. Cancer Res. 80:1102. PubMed
  150. Dey P, et al. 2020. Cancer Discov. 10:608. PubMed
  151. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  152. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  153. Kang JG, et al. 2020. PLoS Negl Trop Dis. 14:e0007813. PubMed
  154. Gorgun FM, et al. 2021. Front Oncol. 11:701968. PubMed
  155. Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed
  156. Fujimura N, et al. 2016. J Vasc Surg. 64: 46-54. PubMed
  157. Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed
  158. Cole C, et al. 2018. Nucleic Acids Res. 46:e62. PubMed
  159. Sutherland APR, et al. 2019. Sci Rep. 9:15302. PubMed
  160. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  161. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  162. Pittala S, et al. 2018. Neoplasia. 9:20222. PubMed
  163. Lin J, et al. 2017. Nat Commun. . 10.1038/s41467-017-01477-5. PubMed
  164. Huppé CA, et al. 2018. Mucosal Immunol. 0.536111111. PubMed
  165. Lee YJ, et al. 2018. FASEB J. 32:4658. PubMed
  166. Atif SM, et al. 2019. JCI Insight. 4:e125494. PubMed
  167. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  168. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
  169. Genton C, et al. 2006. J Immunol. 177:2285. PubMed
  170. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
  171. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  172. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  173. Zhang N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  174. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  175. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  176. Liu H, et al. 2022. Animal Model Exp Med. 5:72. PubMed
  177. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  178. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
  179. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
  180. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
  181. Fritz Y, et al. 2017. J Invest Dermatol. 137:696. PubMed
  182. Chen YQ, et al. 2019. J Immunother Cancer. 0.415277778. PubMed
  183. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
RRID
AB_312740 (BioLegend Cat. No. 100701)
AB_312740 (BioLegend Cat. No. 100702)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 5    Revision Date: 12/03/2020

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account